Clinical Research Directory
Browse clinical research sites, groups, and studies.
The BAARD Study : Evaluating a Computerized Approach to Treatment Selection in Older Adults With Treatment Resistant Depression.
Sponsor: Washington University School of Medicine
Summary
The goal of this clinical trial is to test whether a personalized approach to treatment selection improves symptoms in older adults with treatment-resistant depression. The main questions it aims to answer is: Will using the BAARD predictive models to select medications lead to better depression outcomes, compared to randomly selecting medications? Researchers will use the BAARD predictive models or random assignment to choose one of two medications to add to patients' current treatment. Patients will be asked to take either aripiprazole or bupropion along with their current medication. Participants will: Take Aripiprazole or Bupropion in addition to their current medication for 10 weeks. Complete follow-up assessments every 1-2 weeks for checkups.
Official title: Biotype-assigned Augmentation Approach in Resistant Late-Life Depression (BAARD): a Randomized Controlled Trial
Key Details
Gender
All
Age Range
60 Years - Any
Study Type
INTERVENTIONAL
Enrollment
300
Start Date
2026-10-01
Completion Date
2029-09-15
Last Updated
2026-10-16
Healthy Volunteers
No
Conditions
Interventions
Aripiprazole Augmentation
Aripiprazole augmentation will be started at 2 mg and increased based on symptoms and tolerability up to a maximum dose of 15 mg.
Bupropion Augmentation
Bupropion augmentation will be started at 150 mg and increased based on symptoms and tolerability up to a maximum dose of 450 mg.
Locations (3)
Washington University School of Medicine
St Louis, Missouri, United States
UPMC Western Psychiatric Hospital
Pittsburgh, Pennsylvania, United States
Center for addiction and Mental Health (CAMH)
Toronto, Ontario, Canada